Screening Study for Men at High Genetic Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT03805919 (https://clinicaltrials.gov/show/NCT03805919)
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
Study Contact Information:
Anna Couvillon, Nurse Practitioner
By phone: (240) 858-3148
or by email
About the Study
The National Cancer Institute opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation.
View the study on ClinicalTrials.gov or contact Anna Couvillon, NP at: (240) 858-3148 or by email.
What the Study Entails
- Screening MRI of the prostate every 2 years
- Annual PSA blood test
- Biopsy of the prostate if any MRIs are abnormal
- No cost for study-related tests or procedures
- No cost for travel
- Clinical information will be shared with you and your doctor, if you choose
- Genetic testing is not offered as part of the study
Study Lead Investigator
Fatima Karzai, MD, National Cancer Institute (NCI)
Study Site
The National Institutes of Health (NIH), Clinical Center
Bethesda, MD in the Washington, DC metro area
NIH can cover the cost of travel for participants
This Study is Open To:
Men, and people assigned male at birth are eligible if they:
- are between the ages 30 - 75 years old
- do not have prostate cancer, and
- have had genetic testing and have any of the following: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM) mutation.
This Study is Not Open To:
- People who have already been diagnosed with prostate cancer
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.